Value through Innovation11 February 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


First human data show promise of Boehringer Ingelheim's specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation

- For media outside of the US, the UK & Canada only

Boehringer Ingelheim goes "Blue" in supporting World Diabetes Day activities


Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over

- For Media outside the U.S., Canada and UK

Boehringer Ingelheim supports victims of typhoon Haiyan in the Philippines


New efficacy and safety data for Pradaxa® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013

- For media outside of the US, the UK & Canada only

Micardis crosses 50 million patient-years of experience on 15th anniversary

- For NON-US and NON-UK Healthcare Media Only

New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) with efficacy and safety in specific patient populations

- For Non-US and Non-UK Media

New survey in four major Asian countries reveals complexity of managing Type 2 Diabetes is currently underestimated1

- Ex-US & Ex- UK Medical Media Only

Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C

- For media outside of the U.S.A., UK and Canada only

Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data

- For media outside of the U.S.A., UK and Canada only

New data show Striverdi® (olodaterol)* Respimat® improves exercise tolerance in patients with moderate to very severe COPD1

- For media outside the UK, U.S. and Canada

Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim


New efficacy and safety data adds to evidence supporting treatment with afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients

- For NON-US media only

New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries

- For media outside the UK, U.S. and Canada

Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval

- For non U.S. Media Only

Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

- For media outside of the U.S.A., UK and Canada only

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin

- For media outside of the US, the UK & Canada only

Ben Venue Laboratories, Inc. to Cease Production